Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seretide vs Tiotropium in Severe COPD (INSPIRE)
NCT00361959Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2003
- Primary completion
- Feb 2006
- Countries
- 20
01
Overview
Phase 4, randomised, double-blind trial of salmeterol + fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Rate of healthcare utilisation based exacerbations of COPD at 104 weeks. Started Jun 2003; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00361959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361959.